Logo1
SITC 2019 Annual Meeting (ABIM MOC Credit Only)
Mr pencil

How would you like your name to appear on your certificate?



What activities did you attend at the event?
Agreement
By completing this form, you attest that you have participated in all selected activities in thier entirety.
What is your professional role? (Select all that apply)
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
Did you attend the session in its entirety?
If your professional role was not listed above, please list it here:
Which of the following best describes your primary work setting?
What is your area of specialization?
If your area of specialization was not listed above, please list it here:
How long have you been in practice (if applicable)?
How many patients with cancer do you currently see each week (if applicable)?
Please select the extent to which you agree/disagree that the 34th Annual Meeting supported the achievement of each learning objective:
Summarize and integrate the most recent advances in tumor immunology and cancer immunotherapy into basic, clinical and translational research.
Analyze cutting-edge clinical trials to incorporate new research and techniques into clinical applications for cancer immunotherapy.
Describe immune regulatory pathways that restrict and enhance immunity to tumor antigens, and identify respective targets for therapeutic intervention.
Please select the extent to which you agree/disagree that the 34th Annual Meeting achieved the following:
The activity enhanced my current knowledge base.
The educational material provided useful information for my practice or research.
The content of this activity was fair, balanced, objective, and free of bias.
The faculty were effective in presenting materials.
The content was evidence based.
The activity provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, Q&A, etc.).
The opportunities provided to assess my own learning were appropriate (e.g., questions before, during or after the activity).
If you perceived commercial bias in the 34th Annual Meeting, please indicate the presenter and topic.
Based upon your participation in this activity, do you intend to change your practice behavior?
If you intend to change your approach to patient management, how confident are you that you will be able to make your intended changes?
Apply latest guidelines
I will be more likely to refer a patient to a clinical trial
Change in pharmacological therapy
Change in diagnostic testing (e.g. biomarker testing)
Change in how or when I refer patients to other specialists
Change in how or when I ask my patients about symptoms indicative of irAEs
I will be more likely to combine different immune-based therapies (together or with other agents)
Seek additional support to initiate IO treatment
If you need more information before you are able to change your approach to patient management, what information would be helpful?
Thinking about how your participation in this activity will influence your patient care, how many of your patients are likely to benefit in the next 3 months?
Which of the following do you anticipate will be the primary barrier to implementing these changes?
Would you recommend the SITC Annual Meeting & Pre-Conference Programs to a colleague?
What other topics would you like to see addressed at future SITC Annual Meetings and Pre-Conference Programs?
Please rate the following:
Access to faculty
Quality of the content presented
Panel discussions
Expert discussants
Networking opportunities
SITC meeting app
Experience with complimentary Wi-Fi
In what form would you prefer to receive the Final Program [and Abstract book]?
What types of enduring materials could be produced as a result of this meeting, or through other efforts of SITC that you would find valuable?
If your selection for the question above was 'Other' please provide your answer here.  Please be specific.
How to you prefer to receive the type of information/education presented in this meeting?
If your selection to the question above was 'Other' please provide your answer here. Please be specific.
What social media technologies do you use professionally? (Select all that apply.)
If your selection to the question above was 'Other' please provide your answer here. Please be specific.
How did you first hear about this program?
Other than SITC, what organizations and/or resources do you utilize to receive updates and information about the field of cancer immunotherapy?
Please provide your name, email address and area of interest should you wish to be more involved in SITC or would like to become a member.
What is the biggest hurdle facing the field and how could SITC help address it?
Please leave additional feedback on how SITC can improve your experience next year.
Please enter your ABIM ID number:
For ABIM upload, please enter the month and day of your date of birth, as MM/DD
Example: January 9 would be entered as 01/09
Mr question
Provided by amedco